ClinicalTrials.gg

Program

Varegacestat Test Formulation A

Also written as “Varegacestat Test Formulation B” and “Varegacestat Test Formulation C”.

Its studies are led by Immunome.

Furthest: phase 1, since May 20, 20261 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunome11 open or runningphase 1since May 20, 2026May 20, 2026May 2027phase 1 · NCT07610005

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2026First study: phase 1 study in HealthyFirst studyNCT07610005 · 44 planned · United States

Ahead

  1. May 2027Primary completion: phase 1 study in HealthyNCT07610005

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07610005Healthy · United States1RecruitingMay 202744

How it is read

Names in the registry

  • “Varegacestat Test Formulation A”, 1 entry
  • “Varegacestat Test Formulation B”, 1 entry
  • “Varegacestat Test Formulation C”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.